Malaysia's AirAsia Group Bhd plans to launch an air taxi service and the country's first drone delivery service as the budget carrier seeks to diversify amid the coronavirus pandemic, the company's CEO said on Saturday. The service should start operating in about 18 months, Fernandes was quoted as saying. He also announced that the airline's logistics unit Teleport, which is currently testing an urban drone delivery service with state-backed firm Malaysian Global Innovation and Creativity Centre (MaGIC), would conduct its first commercial delivery by the end of this year.
The singer said she was 'grateful for science and grateful for medicine' in a post to Instagram.
The space tourism company is not having the first quarter investors were hoping for, and its second quarter will probably be another disappointment.
Moderna (NASDAQ: MRNA) recently reported its first-ever product revenue thanks to coronavirus vaccine sales. In this Motley Fool Live video recorded on Feb. 26, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss two encouraging points from the company's fourth-quarter earnings report -- and one reason for caution. Corinne Cardina: What are two green flags for investors and one potential red or yellow flag to pay attention to?
BT denied any "misalignment" between board and management on Saturday after Sky News said that CEO Philip Jansen had indicated he might resign unless it replaced its chairman. The British broadband and mobile telecoms operator said on Monday that Jan du Plessis, who was appointed chairman in November 2017, had informed the board of his intention to retire once a successor has been appointed. On Friday Sky News reported that Jansen, who joined BT as CEO in 2019, had told fellow directors he was frustrated with the speed at which it was taking key strategic decisions.
Personal finance guru Suze Orman said the receipt of a tax refund indicates "something's radically wrong," since the money returned to filers could otherwise have accrued value over the period it stood in the government's possession.
Before we get any further down this asset-class struggle -- pitting crypto against Wall Street -- I want to lay it all out here. The value of Bitcoin (CRYPTO: BTC) has nearly quadrupled since I began warming up to the leading form of cryptocurrency nearly five months ago. Let me show you what I'm buying, and how, when it comes to choosing between asset classes, you can have your stock and crypto, too.
Arsenal will be looking to build on last weekend’s excellent win over Leicester when they travel to Burnley this lunchtime. The Gunners have had the rare benefit of a free midweek ahead of the trip to Turf Moor, and with a fair gap until the crucial last-16 Europa League clash with Olympiacos on Thursday, Mikel Arteta seems likely to recall the likes of Pierre-Emerick Aubameyang and Bukayo Saka.
Becoming financially independent (FI) is a dream for many investors. On a Fool Live episode recorded on Feb. 19, Fool contributors Brian Feroldi, Jason Hall, and Brian Withers discuss the most common rule of thumb for calculating your FI number and what else you should consider. Brian Withers: Let's talk a little bit about the math.
The Lions are scheduled to visit South Africa for eight matches between July 3 and Aug. 7, including three tests against the world champion Springboks. A South African Rugby spokesperson confirmed to Reuters in January that they had received an offer from Australia, who have been relatively successful in containing the pandemic, to host the tour.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new, long-term data from open-label extensions (OLE) of two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF), demonstrating the sustained efficacy and safety profile and no treatment-emergent resistance with Biktarvy for the treatment of HIV-1 in treatment-naïve adults. The data were presented at the 28th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2021).
Investors will soon learn how the COVID-19 pandemic affected the online personalized styling service's fiscal Q2 results.
The Columbia law professor joins the National Economic Council as special assistant to the president for technology and competition policy.
The week in classical: London Unwrapped: Aurora Orchestra; Oxford Lieder festival – reviewKings Place, London, live stream; Holywell Music Room, Oxford, available onlineKings Place’s year-long celebration of the capital’s musical past kicks off with Mendelssohn in Camberwell… Perfect fit… principal players of Aurora Orchestra launch Kings Place’s London Unwrapped series.. Photograph: Nick Rutter
While it doesn’t influence our opinions of products, we may receive compensation from partners whose offers appear here. We’re on your side, always. See our full advertiser disclosure. Image source: Getty Images My nine-year-old has always liked numbers -- and he's always been interested in money.
The White House delivered good news to a pandemic-fatigued public this week, moving up the timeline for vaccine distribution. President Joe Biden said there should be enough vaccine supply for every American adult to get a jab by the end of May. That's two months ahead of previous estimates. Here's why three Fools are backing Spirit Airlines (NYSE: SAVE), Ford Motor (NYSE: F), and Dine Brands Global (NYSE: DIN) to benefit as things reopen and we get back to our normal ways.
High Lung Levels of Active Triphosphate Predicted with Oral AT-527 for COVID-19 Patients Data Supportive of AT-527 550 mg BID Dosing Regimen BOSTON, March 06, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented results from the Phase 1 study of AT-527 in healthy volunteers at the 28th Annual Conference on Retroviruses and Opportunistic Infections (CROI) in a Science Spotlight presentation. AT-527 is an orally administered, direct-acting antiviral developmental agent derived from Atea’s purine nucleotide prodrug platform and is in Phase 2 clinical development for the treatment of COVID-19. AT-527 targets SARS-CoV-2 ribonucleic acid (RNA) polymerase (nsp12), a highly conserved gene which is responsible for both viral RNA replication and transcription. Given this preferential conserved target site, it is anticipated that the antiviral activity of AT-527 will continue even in the presence of naturally-evolving variants which are now emerging. “We were delighted to present these encouraging results at CROI. Since the respiratory tract is the initiation site of the SARS-CoV-2 infection, these data demonstrate the potential for AT-527, our oral antiviral, to have meaningful clinical uptake in the lungs. Specifically, the data demonstrating rapid attainment of steady state with a fast build-up of trough levels enables us to predict that there should be exposure of drug in the lung above levels that are needed to inhibit viral replication,” said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea Pharmaceuticals. “In addition, these results show that AT-527 was well tolerated with a favorable safety and pharmacokinetic profile and are supportive of the dosing regimen for the upcoming Phase 3 program.” In the Phase 1 study, 20 healthy volunteers were randomized 1:1 to receive oral AT-527 550 mg twice daily (BID) or matching placebo for 5 days. The purpose of this study was to assess the safety and pharmacokinetics (PK) of AT-527 in healthy volunteers and to predict human lung exposure of intracellular AT-9010, the active triphosphate (TP) metabolite of AT-527. Safety assessments included adverse events (AEs), vital signs, electrocardiograms (ECGs), and standard safety laboratory tests. Intensive PK sampling, performed after the first and last two doses, provided information on plasma exposures of AT-511, the free base of AT-527, a hemisulfate salt, and its metabolites including AT-273, the guanosine nucleoside metabolite, a measurable surrogate for intracellular AT-9010. The study results showed AT-527 was well tolerated with a favorable safety profile. There were no discontinuations, serious AEs, clinically significant changes in vital signs, or ECGs observed. The data also demonstrated that AT-511 was rapidly absorbed, followed by fast and extensive stepwise metabolic activation ultimately to the intracellular TP metabolite AT-9010, reflected by plasma AT-273. AT-527 550 mg BID led to fast attainment of steady-state levels of AT-273 within two days of dosing. Plasma levels of AT-273 were further used to predict lung concentrations of AT-9010 using a scaling factor of 1.2X which was previously determined from in vivo tissue distribution of the triphosphate metabolite in cynomolgus monkeys. Beginning as early as three hours after the first dose, and maintained thereafter throughout the five days of dosing, predicted lung AT-9010 levels were consistently above the EC90 level of 0.5 µM for in vitro inhibition by the drug of SARS-CoV-2 replication. These results indicate the potential of AT-527 for the treatment of COVID-19 and are supportive of the dosing regimen of 550 mg BID. About AT-527 AT-527 is an orally administered, direct-acting developmental antiviral agent derived from Atea’s nucleotide prodrug platform. AT-527 is currently under evaluation as a treatment for patients with COVID-19. In collaboration with Roche, AT-527 is currently being evaluated in a global Phase 2 study for hospitalized patients with moderate COVID-19 and a Phase 2 virology study in patients with mild or moderate COVID-19 in an outpatient setting. A pivotal Phase 3 trial is planned in the outpatient setting. A direct-acting antiviral aims to prevent disease progression by minimizing or eliminating viral replication and thereby reducing the severity of the disease, preventing or shortening hospitalization, and also potentially preventing transmission of the virus to others. This makes it well suited for potential use in both pre- and post-exposure prophylactic settings and complementary to vaccines. About Atea Pharmaceuticals Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com. Contacts Investors: Jonae BarnesSVP, Investor Relations and Corporate Communications617-818-2985Barnes.firstname.lastname@example.org Will O’ConnorStern Investor Relations email@example.com Media: Carol Guaccero301firstname.lastname@example.org
Follow the latest updates and statistics
Zlatan Ibrahimovic will return to international football at the age of 39, Swedish media reported on Saturday.
Wells Fargo (NYSE: WFC) has been one of the financial sector's worst performers for several years. Not only did the bank's "fake accounts" scandal and Federal Reserve penalty hurt performance, but the consumer-focused bank was hit harder than most by the COVID-19 pandemic. Not only that, but it appears one of the bank's longtime fans and shareholders, Warren Buffett, has given up on Wells Fargo as an investment.